CIK 0001590750 · Large accelerated filer
Viridian Therapeutics, Inc.\DE
Sign in to watch- Ticker
- VRDN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 471187261
- Phone
- 617.272.4600
- Business address
- 221 CRESCENT STREET, SUITE 103A, WALTHAM, MA, 02453
- Former names
- MIRAGEN THERAPEUTICS, INC., SIGNAL GENETICS, INC., SIGNAL GENETICS LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $348,194
- in 1 filing
Net −$348,194. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-12-15 | Meisner Lara General Counsel and Secretary | Option exercise | +300 | $23.03 | $7K | 300 |
| 2022-12-15 | Meisner Lara General Counsel and Secretary | Sale | −300 | $28.08 | $8K | 0 |
| 2022-12-15 | Meisner Lara General Counsel and Secretary | Option exercise · Stock Option (Right to Buy) | −300 | 62,944 | ||
| 2022-12-14 | Meisner Lara General Counsel and Secretary | Option exercise | +15,656 | $23.03 | $361K | 15,656 |
| 2022-12-14 | Meisner Lara General Counsel and Secretary | Sale | −15,656 | $28.12 | $440K | 0 |
| 2022-12-14 | Meisner Lara General Counsel and Secretary | Option exercise · Stock Option (Right to Buy) | −15,656 | 63,244 | ||
| 2022-12-12 | Meisner Lara General Counsel and Secretary | Option exercise | +600 | $23.03 | $14K | 600 |
| 2022-12-12 | Meisner Lara General Counsel and Secretary | Sale | −600 | $28.05 | $17K | 0 |
| 2022-12-12 | Meisner Lara General Counsel and Secretary | Option exercise · Stock Option (Right to Buy) | −600 | 78,900 | ||
| 2022-11-15 | Meisner Lara General Counsel and Secretary | Option exercise | +8,125 | $14.00 | $114K | 8,125 |
| 2022-11-15 | Meisner Lara General Counsel and Secretary | Sale | −8,125 | $22.05 | $179K | 0 |
| 2022-11-15 | Meisner Lara General Counsel and Secretary | Option exercise · Stock Option (Right to Buy) | −8,125 | 21,875 | ||
| 2022-08-17 | Fairmount Funds Management LLC Director | Purchase | +425,531 | $23.50 | $10.0M | 1,363,764 |
| 2022-06-08 | Moses Jennifer K. Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2022-06-08 | Kiselak Tomas Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2022-06-08 | Harwin Peter Evan Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2022-06-08 | Morris Arlene Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2022-06-01 | Violin Jonathan Chief Executive Officer | Sale | −30,000 | $12.20 | $366K | 480,905 |
| 2022-05-02 | Violin Jonathan Chief Executive Officer | Sale | −30,000 | $13.04 | $391K | 510,905 |
| 2022-04-04 | Violin Jonathan Chief Executive Officer | Sale | −3,600 | $18.93 | $68K | 540,905 |
Page 8 of 10 · 182 trades